aspirin has been researched along with Infant, Small for Gestational Age in 36 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Infant, Small for Gestational Age: An infant having a birth weight lower than expected for its gestational age.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Trial will be individually randomized with one-to-one ratio (intervention/control) Population: Nulliparous women between the ages of 14 and 40, with a singleton pregnancy between 6 0/7 weeks and 13 6/7 weeks gestational age (GA) confirmed by ultrasound prior to enrollment, no more than two previous first trimester pregnancy losses, and no contraindications to aspirin." | 9.24 | A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study. ( Bose, CL; Carlo, WA; Chomba, E; Derman, RJ; Esamai, F; Garces, A; Goco, N; Goldenberg, RL; Goudar, SS; Hambidge, KM; Hemingway-Foday, JJ; Hibberd, PL; Hoffman, MK; Kodkany, BS; Koso-Thomas, M; Krebs, NF; Liechty, EA; Lokangaka, A; McClure, EM; Miodovnik, M; Mwenechanya, M; Patel, A; Saleem, S; Silver, R; Tshefu, A; Wallace, DD, 2017) |
| "In this population of women with aPLA, who had previously had an early delivery for HD and/or SGA prior to 34 weeks gestation, combined LMWH and aspirin treatment started before 12 weeks gestation in a subsequent pregnancy did not show reduction of onset of recurrent HD either <34 weeks gestation or irrespective of gestational age, compared with aspirin alone." | 9.22 | Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016) |
| "Aspirin supplementation was associated with worse outcomes related to preterm birth in smokers in a high-risk but not low-risk cohort." | 9.20 | Low-dose aspirin, smoking status, and the risk of spontaneous preterm birth. ( Abramovici, A; Biggio, J; Cantu, J; Edwards, R; Jauk, V; Tita, A; Wetta, L, 2015) |
| "Daily low-dose aspirin during pregnancy was associated with lower risks of serious perinatal outcomes for individuals at increased risk for preeclampsia, without evident harms." | 9.12 | Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Henderson, JT; Redmond, N; Senger, CA; Thomas, RG; Vesco, KK, 2021) |
| "We assessed the effects and safety of aspirin treatment during pregnancy on fetal and neonatal outcomes." | 8.82 | Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. ( Boskovic, R; Costei, AM; Koren, G; Kozer, E; Nikfar, S; Nulman, I, 2003) |
| "To evaluate the prevalence and perinatal repercussions of preeclampsia (PE) after the implementation of a prophylaxis protocol with aspirin in singleton pregnancy at Maternity School of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (2015-2106)." | 8.31 | The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin. ( Amim, J; Bornia, RG; Cardoso, FFO; Cardoso, MIMP; Costa Junior, IB; Da Matta, FG; Gama, LB; Rezende, KBC; Saunders, C, 2023) |
| "To estimate whether low-dose aspirin use is associated with an altered risk of delivering a small-for-gestational age (SGA) neonate among women with a history of having an SGA neonate in a prior pregnancy." | 8.12 | Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy. ( Bergman, L; Cluver, CA; Hastie, R; Hesselman, S; Kupka, E; Lindquist, A; Tong, S; Walker, SP; Wikström, AK, 2022) |
| "The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia." | 8.02 | Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Cabana, M; Caughey, AB; Davidson, KW; Davis, EM; Donahue, KE; Doubeni, CA; Kubik, M; Li, L; Mangione, CM; Ogedegbe, G; Pbert, L; Silverstein, M; Simon, MA; Stevermer, J; Tseng, CW; Wong, JB, 2021) |
| " Among 932 women, 277 in the First Affiliated Hospital of Chongqing Medical University were routinely treated with aspirin (100 mg daily) from 12 to 16 weeks to 35 weeks of gestational age, while 655 in Chongqing Health Center for Women and Children were not taking aspirin during pregnancy." | 8.02 | Low-dose aspirin for primary prevention of adverse pregnancy outcomes in twin pregnancies: an observational cohort study based on propensity score matching. ( Baker, P; Kilby, MD; Liu, X; Liu, Y; Qi, H; Saffery, R; Tong, C; Wang, L; Wen, L; Ye, Y, 2021) |
| "Aspirin has been shown to reduce prevalence of both early-onset pre-eclampsia (ePET) and fetal growth restriction (FGR)." | 8.02 | Does aspirin prescribed to women deemed high risk for preterm pre-eclampsia at 11-13 ( Emeto, T; Hyett, J; O'Brien, C; Park, F; Phung, J, 2021) |
| "To evaluate the effect of low-dose aspirin, which was administered at or before the 16th week of pregnancy due to maternal characteristics and history of a pre-existing medical condition, on prevention of pre-eclampsia, and on the birth of a small-for-gestational-age (SGA) neonate without pre-eclampsia in nulliparas in primary settings." | 7.96 | Effect of current guidelines on prevention of pre-eclampsia with low-dose aspirin in primary settings: A population-based case-control study. ( Kocic, Z; Premru-Srsen, T; Verdenik, I, 2020) |
| "Aspirin resistance may be associated with increased risk of adverse pregnancy outcomes including preeclampsia, premature delivery and delivery of SGA newborns." | 7.77 | Aspirin resistance may be associated with adverse pregnancy outcomes. ( Huras, H; Jach, R; Musiał, J; Reroń, A; Rytlewski, K; Undas, A; Wilczak, M; Wójtowicz, A, 2011) |
| "Outcomes included preeclampsia (mild and severe) and SGA neonates." | 6.53 | Prevention of Preeclampsia with Aspirin in Multiple Gestations: A Systematic Review and Meta-analysis. ( Bergeron, TS; Bujold, E; Carpentier, C; McCaw-Binns, A; Roberge, S; Sibai, B, 2016) |
| "Outcomes included preeclampsia, severe preeclampsia, and SGA." | 6.53 | Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials. ( Bujold, E; McCaw-Binns, A; Roberge, S; Sibai, B, 2016) |
| "This is a single site sub-study of data collected in conjunction with the Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN) Trial, which is listed at ClinicalTrials." | 5.69 | Birth weight and gestational age distributions in a rural Kenyan population. ( Achieng, E; Bucher, S; Ekhaguere, OA; Esamai, FO; Kemboi, M; Liechty, EA; Marete, I; Nowak, K; Nyongesa, P; Otieno, K; Rutto, F; Tenge, C, 2023) |
| " Trial will be individually randomized with one-to-one ratio (intervention/control) Population: Nulliparous women between the ages of 14 and 40, with a singleton pregnancy between 6 0/7 weeks and 13 6/7 weeks gestational age (GA) confirmed by ultrasound prior to enrollment, no more than two previous first trimester pregnancy losses, and no contraindications to aspirin." | 5.24 | A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study. ( Bose, CL; Carlo, WA; Chomba, E; Derman, RJ; Esamai, F; Garces, A; Goco, N; Goldenberg, RL; Goudar, SS; Hambidge, KM; Hemingway-Foday, JJ; Hibberd, PL; Hoffman, MK; Kodkany, BS; Koso-Thomas, M; Krebs, NF; Liechty, EA; Lokangaka, A; McClure, EM; Miodovnik, M; Mwenechanya, M; Patel, A; Saleem, S; Silver, R; Tshefu, A; Wallace, DD, 2017) |
| "In women with defective trophoblastic invasion, as reflected by abnormal UtA Doppler, low-dose aspirin started in the first trimester does not have a significant effect on UtA impedance as pregnancy progresses; however, the study was underpowered to detect potential small effects ." | 5.24 | Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11-14 weeks: a randomized controlled study. ( Diaz, D; Figueras, F; González de Agüero, R; Gratacos, E; Meler, E; Oros, D; Ramirez, JC; Ricart, M; Scazzocchio, E, 2017) |
| "In this population of women with aPLA, who had previously had an early delivery for HD and/or SGA prior to 34 weeks gestation, combined LMWH and aspirin treatment started before 12 weeks gestation in a subsequent pregnancy did not show reduction of onset of recurrent HD either <34 weeks gestation or irrespective of gestational age, compared with aspirin alone." | 5.22 | Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016) |
| "Aspirin supplementation was associated with worse outcomes related to preterm birth in smokers in a high-risk but not low-risk cohort." | 5.20 | Low-dose aspirin, smoking status, and the risk of spontaneous preterm birth. ( Abramovici, A; Biggio, J; Cantu, J; Edwards, R; Jauk, V; Tita, A; Wetta, L, 2015) |
| "Daily low-dose aspirin during pregnancy was associated with lower risks of serious perinatal outcomes for individuals at increased risk for preeclampsia, without evident harms." | 5.12 | Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Henderson, JT; Redmond, N; Senger, CA; Thomas, RG; Vesco, KK, 2021) |
| "The results did not demonstrate a significant difference amongst low risk nulliparous women in the risks of pre-eclampsia or gestational hypertensive disorders with aspirin administration." | 5.12 | Aspirin for preventing adverse outcomes in low risk nulliparous women with singleton pregnancies: A systematic review and meta-analysis. ( Devani, P; Hodgetts Morton, V; Man, R; Morris, RK, 2021) |
| "This was a prospective observation of pregnancy outcomes among 462 women with pregestational diabetes mellitus (White classes B-F) and singleton pregnancies who were enrolled in a multicenter trial to compare low-dose aspirin with placebo for preeclampsia prevention." | 5.09 | Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, S; Dombrowski, M; Hauth, J; Klebanoff, M; Landon, M; Lindheimer, M; MacPherson, C; McNellis, D; Meis, P; Miodovnik, M; Paul, R; Roberts, J; Sibai, BM; Thurnau, G; VanDorsten, JP, 2000) |
| "Administering low-dose aspirin to pregnant women led to small-to-moderate benefits, including reductions in pre-eclampsia (16 fewer per 1000 women treated), preterm birth (16 fewer per 1000 treated), the baby being born small-for-gestational age (seven fewer per 1000 treated) and fetal or neonatal death (five fewer per 1000 treated)." | 5.01 | Antiplatelet agents for preventing pre-eclampsia and its complications. ( Askie, LM; Duley, L; Hunter, KE; Meher, S; Seidler, AL, 2019) |
| " There is general consensus between guidelines (at least 4 of 6 guidelines in agreement) in early pregnancy risk selection, and use of low-dose aspirin for women with major risk factors for placental insufficiency." | 4.98 | Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. ( Anderson, NH; Figueras, F; McCowan, LM, 2018) |
| "We assessed the effects and safety of aspirin treatment during pregnancy on fetal and neonatal outcomes." | 4.82 | Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. ( Boskovic, R; Costei, AM; Koren, G; Kozer, E; Nikfar, S; Nulman, I, 2003) |
| "To evaluate the prevalence and perinatal repercussions of preeclampsia (PE) after the implementation of a prophylaxis protocol with aspirin in singleton pregnancy at Maternity School of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (2015-2106)." | 4.31 | The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin. ( Amim, J; Bornia, RG; Cardoso, FFO; Cardoso, MIMP; Costa Junior, IB; Da Matta, FG; Gama, LB; Rezende, KBC; Saunders, C, 2023) |
| "To estimate whether low-dose aspirin use is associated with an altered risk of delivering a small-for-gestational age (SGA) neonate among women with a history of having an SGA neonate in a prior pregnancy." | 4.12 | Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy. ( Bergman, L; Cluver, CA; Hastie, R; Hesselman, S; Kupka, E; Lindquist, A; Tong, S; Walker, SP; Wikström, AK, 2022) |
| " Among 932 women, 277 in the First Affiliated Hospital of Chongqing Medical University were routinely treated with aspirin (100 mg daily) from 12 to 16 weeks to 35 weeks of gestational age, while 655 in Chongqing Health Center for Women and Children were not taking aspirin during pregnancy." | 4.02 | Low-dose aspirin for primary prevention of adverse pregnancy outcomes in twin pregnancies: an observational cohort study based on propensity score matching. ( Baker, P; Kilby, MD; Liu, X; Liu, Y; Qi, H; Saffery, R; Tong, C; Wang, L; Wen, L; Ye, Y, 2021) |
| "The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia." | 4.02 | Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Cabana, M; Caughey, AB; Davidson, KW; Davis, EM; Donahue, KE; Doubeni, CA; Kubik, M; Li, L; Mangione, CM; Ogedegbe, G; Pbert, L; Silverstein, M; Simon, MA; Stevermer, J; Tseng, CW; Wong, JB, 2021) |
| "Aspirin has been shown to reduce prevalence of both early-onset pre-eclampsia (ePET) and fetal growth restriction (FGR)." | 4.02 | Does aspirin prescribed to women deemed high risk for preterm pre-eclampsia at 11-13 ( Emeto, T; Hyett, J; O'Brien, C; Park, F; Phung, J, 2021) |
| "To evaluate the effect of low-dose aspirin, which was administered at or before the 16th week of pregnancy due to maternal characteristics and history of a pre-existing medical condition, on prevention of pre-eclampsia, and on the birth of a small-for-gestational-age (SGA) neonate without pre-eclampsia in nulliparas in primary settings." | 3.96 | Effect of current guidelines on prevention of pre-eclampsia with low-dose aspirin in primary settings: A population-based case-control study. ( Kocic, Z; Premru-Srsen, T; Verdenik, I, 2020) |
| " In ASPRE, women with a singleton pregnancy identified by combined screening as being at high risk for preterm PE (> 1 in 100) participated in a trial of aspirin (150 mg/day from 11-14 until 36 weeks' gestation) compared to placebo." | 3.88 | Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE. ( Akolekar, R; Cicero, S; de Paco Matallana, C; Greco, E; Janga, D; Jani, JC; Molina, FS; Nicolaides, KH; Papaioannou, G; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Singh, M; Syngelaki, A; Tan, MY; Wright, D, 2018) |
| "Aspirin resistance may be associated with increased risk of adverse pregnancy outcomes including preeclampsia, premature delivery and delivery of SGA newborns." | 3.77 | Aspirin resistance may be associated with adverse pregnancy outcomes. ( Huras, H; Jach, R; Musiał, J; Reroń, A; Rytlewski, K; Undas, A; Wilczak, M; Wójtowicz, A, 2011) |
| "To evaluate the pregnancy outcome in patients with abnormal uterine artery Doppler flow velocity waveforms (FVW's) at 19-21 weeks, which were subsequently normal by 24-26 weeks, and to study the effect of low-dose aspirin on these waveforms." | 3.72 | Delayed normalization of uterine artery Doppler waveforms is not a benign phenomenon. ( Fayyad, A; Harrington, K; Kurdi, W; Thakur, V, 2004) |
| "Aspirin was significantly associated with a higher birthweight Z-score (0." | 2.84 | Impact of aspirin on fetal growth in diabetic pregnancies according to White classification. ( Adkins, K; Allshouse, AA; Heyborne, KD; Metz, TD, 2017) |
| "When superimposed preeclampsia was present, it developed at an earlier gestational age among the group without GDM (35 ± 5 vs." | 2.82 | Rate of Gestational Diabetes Mellitus and Pregnancy Outcomes in Patients with Chronic Hypertension. ( Blackwell, SC; Haidar, ZA; Leon, MG; Longo, M; Mendez-Figueroa, H; Moussa, HN; Pedroza, C; Sibai, BM, 2016) |
| "Women with a prior pregnancy affected by FGR have a 20% to 30% risk of recurrence, but effective preventive strategies are lacking." | 2.72 | Recurrence Risk of Fetal Growth Restriction: Management of Subsequent Pregnancies. ( Blue, NR; Page, JM; Silver, RM, 2021) |
| "Women at an increased risk of preeclampsia should be offered antiplatelet therapy, regardless of whether they are first seen before or after 16 weeks' gestation." | 2.55 | Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. ( Askie, L; Duley, L; Hunter, K; Meher, S, 2017) |
| "Outcomes included preeclampsia (mild and severe) and SGA neonates." | 2.53 | Prevention of Preeclampsia with Aspirin in Multiple Gestations: A Systematic Review and Meta-analysis. ( Bergeron, TS; Bujold, E; Carpentier, C; McCaw-Binns, A; Roberge, S; Sibai, B, 2016) |
| "Outcomes included preeclampsia, severe preeclampsia, and SGA." | 2.53 | Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials. ( Bujold, E; McCaw-Binns, A; Roberge, S; Sibai, B, 2016) |
| "Treatment with aspirin and LMWH is associated with improved outcomes for women with previous late fetal loss or early delivery due to placental dysfunction (Group 2)." | 1.36 | Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. ( Bewley, S; Bramham, K; Calatayud, I; Germain, S; Hunt, BJ; Khamashta, M; Nelson-Piercy, C, 2010) |
| "No patients with preeclampsia or other severe complications of pregnancy were observed in the normalised group." | 1.31 | Late normalisation of uterine artery velocimetry in high risk pregnancy. ( Danti, L; Frusca, T; Scalvi, L; Soregaroli, M; Valcamonico, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.78) | 18.7374 |
| 1990's | 2 (5.56) | 18.2507 |
| 2000's | 4 (11.11) | 29.6817 |
| 2010's | 16 (44.44) | 24.3611 |
| 2020's | 13 (36.11) | 2.80 |
| Authors | Studies |
|---|---|
| Davidson, KW | 1 |
| Barry, MJ | 1 |
| Mangione, CM | 1 |
| Cabana, M | 1 |
| Caughey, AB | 1 |
| Davis, EM | 1 |
| Donahue, KE | 1 |
| Doubeni, CA | 1 |
| Kubik, M | 1 |
| Li, L | 1 |
| Ogedegbe, G | 1 |
| Pbert, L | 1 |
| Silverstein, M | 1 |
| Simon, MA | 1 |
| Stevermer, J | 1 |
| Tseng, CW | 1 |
| Wong, JB | 1 |
| Henderson, JT | 1 |
| Vesco, KK | 1 |
| Senger, CA | 1 |
| Thomas, RG | 1 |
| Redmond, N | 1 |
| Ye, Y | 1 |
| Wen, L | 1 |
| Liu, X | 1 |
| Wang, L | 1 |
| Liu, Y | 1 |
| Saffery, R | 1 |
| Kilby, MD | 1 |
| Tong, C | 1 |
| Qi, H | 1 |
| Baker, P | 1 |
| Hastie, R | 1 |
| Tong, S | 1 |
| Wikström, AK | 1 |
| Walker, SP | 1 |
| Lindquist, A | 1 |
| Cluver, CA | 1 |
| Kupka, E | 1 |
| Bergman, L | 1 |
| Hesselman, S | 1 |
| Bucher, S | 1 |
| Nowak, K | 1 |
| Otieno, K | 1 |
| Tenge, C | 1 |
| Marete, I | 1 |
| Rutto, F | 1 |
| Kemboi, M | 1 |
| Achieng, E | 1 |
| Ekhaguere, OA | 1 |
| Nyongesa, P | 1 |
| Esamai, FO | 1 |
| Liechty, EA | 2 |
| Joudi, N | 1 |
| Rode, M | 1 |
| Cardoso, MIMP | 1 |
| Rezende, KBC | 1 |
| Da Matta, FG | 1 |
| Saunders, C | 1 |
| Cardoso, FFO | 1 |
| Costa Junior, IB | 1 |
| Gama, LB | 1 |
| Amim, J | 1 |
| Bornia, RG | 1 |
| Duley, L | 2 |
| Meher, S | 2 |
| Hunter, KE | 1 |
| Seidler, AL | 1 |
| Askie, LM | 1 |
| Premru-Srsen, T | 1 |
| Kocic, Z | 1 |
| Verdenik, I | 1 |
| Theilen, LH | 1 |
| Campbell, HD | 1 |
| Mumford, SL | 1 |
| Purdue-Smithe, AC | 1 |
| Sjaarda, LA | 1 |
| Perkins, NJ | 1 |
| Radoc, JG | 1 |
| Silver, RM | 2 |
| Schisterman, EF | 1 |
| Park, F | 1 |
| O'Brien, C | 1 |
| Phung, J | 1 |
| Emeto, T | 1 |
| Hyett, J | 1 |
| Blue, NR | 1 |
| Page, JM | 1 |
| Man, R | 1 |
| Hodgetts Morton, V | 1 |
| Devani, P | 1 |
| Morris, RK | 1 |
| Cruz-Lemini, M | 1 |
| Vázquez, JC | 1 |
| Ullmo, J | 1 |
| Llurba, E | 1 |
| Hoffman, MK | 1 |
| Goudar, SS | 1 |
| Kodkany, BS | 1 |
| Goco, N | 1 |
| Koso-Thomas, M | 1 |
| Miodovnik, M | 2 |
| McClure, EM | 1 |
| Wallace, DD | 1 |
| Hemingway-Foday, JJ | 1 |
| Tshefu, A | 1 |
| Lokangaka, A | 1 |
| Bose, CL | 1 |
| Chomba, E | 1 |
| Mwenechanya, M | 1 |
| Carlo, WA | 1 |
| Garces, A | 1 |
| Krebs, NF | 1 |
| Hambidge, KM | 1 |
| Saleem, S | 1 |
| Goldenberg, RL | 1 |
| Patel, A | 1 |
| Hibberd, PL | 1 |
| Esamai, F | 1 |
| Silver, R | 1 |
| Derman, RJ | 1 |
| Adkins, K | 1 |
| Allshouse, AA | 1 |
| Metz, TD | 1 |
| Heyborne, KD | 1 |
| McCowan, LM | 2 |
| Figueras, F | 2 |
| Anderson, NH | 1 |
| Tan, MY | 1 |
| Poon, LC | 1 |
| Rolnik, DL | 1 |
| Syngelaki, A | 1 |
| de Paco Matallana, C | 1 |
| Akolekar, R | 1 |
| Cicero, S | 1 |
| Janga, D | 1 |
| Singh, M | 1 |
| Molina, FS | 1 |
| Persico, N | 1 |
| Jani, JC | 1 |
| Plasencia, W | 1 |
| Greco, E | 1 |
| Papaioannou, G | 1 |
| Wright, D | 1 |
| Nicolaides, KH | 1 |
| Abramovici, A | 1 |
| Jauk, V | 1 |
| Wetta, L | 1 |
| Cantu, J | 1 |
| Edwards, R | 1 |
| Biggio, J | 1 |
| Tita, A | 1 |
| Moussa, HN | 2 |
| Wu, ZH | 1 |
| Han, Y | 1 |
| Pacheco, LD | 1 |
| Blackwell, SC | 2 |
| Sibai, BM | 3 |
| Saade, G | 1 |
| Costantine, MM | 1 |
| Abheiden, C | 1 |
| Van Hoorn, ME | 2 |
| Hague, WM | 2 |
| Kostense, PJ | 1 |
| van Pampus, MG | 2 |
| de Vries, J | 1 |
| Bergeron, TS | 1 |
| Roberge, S | 2 |
| Carpentier, C | 1 |
| Sibai, B | 2 |
| McCaw-Binns, A | 2 |
| Bujold, E | 2 |
| Bezemer, D | 1 |
| de Vries, JI | 1 |
| Leon, MG | 1 |
| Longo, M | 1 |
| Pedroza, C | 1 |
| Haidar, ZA | 1 |
| Mendez-Figueroa, H | 1 |
| Scazzocchio, E | 1 |
| Oros, D | 1 |
| Diaz, D | 1 |
| Ramirez, JC | 1 |
| Ricart, M | 1 |
| Meler, E | 1 |
| González de Agüero, R | 1 |
| Gratacos, E | 1 |
| Hunter, K | 1 |
| Askie, L | 1 |
| Bramham, K | 1 |
| Hunt, BJ | 1 |
| Germain, S | 1 |
| Calatayud, I | 1 |
| Khamashta, M | 1 |
| Bewley, S | 1 |
| Nelson-Piercy, C | 1 |
| Wójtowicz, A | 1 |
| Undas, A | 1 |
| Huras, H | 1 |
| Musiał, J | 1 |
| Rytlewski, K | 1 |
| Reroń, A | 1 |
| Wilczak, M | 1 |
| Jach, R | 1 |
| Kozer, E | 1 |
| Costei, AM | 1 |
| Boskovic, R | 1 |
| Nulman, I | 1 |
| Nikfar, S | 1 |
| Koren, G | 1 |
| Kurdi, W | 1 |
| Fayyad, A | 1 |
| Thakur, V | 1 |
| Harrington, K | 1 |
| Buist, RG | 1 |
| North, RA | 1 |
| Gamble, G | 1 |
| Caritis, S | 1 |
| Hauth, J | 1 |
| Lindheimer, M | 1 |
| VanDorsten, JP | 1 |
| MacPherson, C | 1 |
| Klebanoff, M | 1 |
| Landon, M | 1 |
| Paul, R | 1 |
| Meis, P | 1 |
| Dombrowski, M | 1 |
| Thurnau, G | 1 |
| Roberts, J | 1 |
| McNellis, D | 1 |
| Soregaroli, M | 1 |
| Valcamonico, A | 1 |
| Scalvi, L | 1 |
| Danti, L | 1 |
| Frusca, T | 1 |
| Wallenburg, HC | 1 |
| van Kessel, PH | 1 |
| van Hof, AC | 1 |
| Ubachs, JM | 1 |
| van Wersch, JW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Best Practice Alert (BPA) for Low Dose Aspirin Recommendation in High-risk Pregnancies: a Randomized Controlled Trial[NCT05802940] | 640 participants (Anticipated) | Interventional | 2023-06-19 | Not yet recruiting | |||
| 162 mg of Aspirin for Prevention of Preeclampsia[NCT05221164] | Phase 4 | 200 participants (Anticipated) | Interventional | 2021-07-06 | Recruiting | ||
| Prevention of Maternal and Neonatal Death/Infections With a Single Oral Dose of Azithromycin in Women in Labor (in Low- and Middle-income Countries): a Randomized Controlled Trial[NCT03871491] | Phase 3 | 34,000 participants (Anticipated) | Interventional | 2020-09-01 | Active, not recruiting | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| Correlation Between Pulmonary Artery Doppler And Other Ultrasonographic Markers With Neonatal Outcome In Placenta Accreta Spectrum Patients[NCT04911322] | 71 participants (Actual) | Observational | 2021-08-15 | Completed | |||
| Correlation Between Pulmonary Artery Doppler And Neonatal Outcome In Hypertensive Disorders Of Pregnancy[NCT05793125] | 72 participants (Anticipated) | Observational | 2023-04-03 | Recruiting | |||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
11 reviews available for aspirin and Infant, Small for Gestational Age
| Article | Year |
|---|---|
Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Infant, Newborn; Infant, Small for | 2021 |
Aspirin in pregnancy: a review of indications, timing, dosing and efficacy.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Infant, Small for Gestational Ag | 2023 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Gestational Age; Humans; Infant, Newborn; Infant, Small for Gestational Age; Matern | 2019 |
Recurrence Risk of Fetal Growth Restriction: Management of Subsequent Pregnancies.
Topics: Adult; Anticoagulants; Aspirin; Delivery, Obstetric; Female; Fetal Growth Retardation; Gestational A | 2021 |
Aspirin for preventing adverse outcomes in low risk nulliparous women with singleton pregnancies: A systematic review and meta-analysis.
Topics: Aspirin; Female; Humans; Infant, Newborn; Infant, Small for Gestational Age; Pre-Eclampsia; Pregnanc | 2021 |
Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Fetal Growth Retardation; Gestational Ag | 2022 |
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F | 2018 |
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F | 2018 |
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F | 2018 |
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F | 2018 |
Prevention of Preeclampsia with Aspirin in Multiple Gestations: A Systematic Review and Meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Infant, Newborn; Infant, Small f | 2016 |
Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Infant, Newborn; Infant, Small f | 2016 |
Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis.
Topics: Aspirin; Female; Humans; Infant, Newborn; Infant, Small for Gestational Age; Perinatal Death; Platel | 2017 |
Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis.
Topics: Abnormalities, Drug-Induced; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Birth Weight; | 2003 |
10 trials available for aspirin and Infant, Small for Gestational Age
| Article | Year |
|---|---|
Birth weight and gestational age distributions in a rural Kenyan population.
Topics: Age Distribution; Aspirin; Birth Weight; Female; Gestational Age; Humans; Infant; Infant, Newborn; I | 2023 |
A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Developing Countries; Double-Bl | 2017 |
A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Developing Countries; Double-Bl | 2017 |
A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Developing Countries; Double-Bl | 2017 |
A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Developing Countries; Double-Bl | 2017 |
Impact of aspirin on fetal growth in diabetic pregnancies according to White classification.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Development; Fetal Macrosomia; Humans; Infant, Newborn; | 2017 |
Low-dose aspirin, smoking status, and the risk of spontaneous preterm birth.
Topics: Adolescent; Adult; Aspirin; Cohort Studies; Double-Blind Method; Female; Humans; Infant, Newborn; In | 2015 |
Customized versus Population Fetal Growth Norms and Adverse Outcomes Associated with Small for Gestational Age Infants in a High-Risk Cohort.
Topics: Aspirin; Birth Weight; Cesarean Section; Cyclooxygenase Inhibitors; Female; Fetal Development; Fetal | 2015 |
Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial Doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results.
Topics: Adult; Anticoagulants; Aspirin; Birth Weight; Blood Flow Velocity; Drug Therapy, Combination; Female | 2016 |
Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Australia; Drug Therapy, Co | 2016 |
Rate of Gestational Diabetes Mellitus and Pregnancy Outcomes in Patients with Chronic Hypertension.
Topics: Adult; Aspirin; Diabetes, Gestational; Female; Gestational Age; Humans; Hypertension; Infant, Newbor | 2016 |
Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11-14 weeks: a randomized controlled study.
Topics: Adult; Aspirin; Cell Movement; Female; Humans; Infant, Small for Gestational Age; Pre-Eclampsia; Pre | 2017 |
Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.
Topics: Aspirin; Birth Weight; Blood Pressure; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; | 2000 |
15 other studies available for aspirin and Infant, Small for Gestational Age
| Article | Year |
|---|---|
Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Infant, Newborn; Infant, Small for | 2021 |
Low-dose aspirin for primary prevention of adverse pregnancy outcomes in twin pregnancies: an observational cohort study based on propensity score matching.
Topics: Adult; Aspirin; China; Cohort Studies; Female; Humans; Infant, Small for Gestational Age; Pre-Eclamp | 2021 |
Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy.
Topics: Aspirin; Birth Weight; Cohort Studies; Female; Fetal Growth Retardation; Gestational Age; Humans; In | 2022 |
The prevalence and perinatal repercussions of preeclampsia after the implementation of a prophylaxis protocol with aspirin.
Topics: Aspirin; Brazil; Female; Fetal Death; Fetal Growth Retardation; Gestational Age; Humans; Infant, New | 2023 |
Effect of current guidelines on prevention of pre-eclampsia with low-dose aspirin in primary settings: A population-based case-control study.
Topics: Adult; Aspirin; Case-Control Studies; Female; Guideline Adherence; Humans; Infant, Newborn; Infant, | 2020 |
Platelet activation and placenta-mediated adverse pregnancy outcomes: an ancillary study to the Effects of Aspirin in Gestation and Reproduction trial.
Topics: Abruptio Placentae; Adult; Aspirin; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnanc | 2020 |
Does aspirin prescribed to women deemed high risk for preterm pre-eclampsia at 11-13
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Infant, Newborn; Infant, Small f | 2021 |
Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE.
Topics: Adult; Aspirin; Biomarkers; Female; Fetal Growth Retardation; Gestational Age; Humans; Infant, Newbo | 2018 |
Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Infant, Ne | 2010 |
Aspirin resistance may be associated with adverse pregnancy outcomes.
Topics: Adult; Aspirin; Cesarean Section; Drug Resistance; Female; Fetal Distress; Humans; Infant, Newborn; | 2011 |
Delayed normalization of uterine artery Doppler waveforms is not a benign phenomenon.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arteries; Aspirin; Case-Control Studies; Delayed-Act | 2004 |
Perinatal morbidity in chronic hypertension.
Topics: Adult; Aspirin; Chronic Disease; Cohort Studies; Female; Fetal Death; Humans; Hypertension; Infant M | 1996 |
Late normalisation of uterine artery velocimetry in high risk pregnancy.
Topics: Arteries; Aspirin; Blood Flow Velocity; Dose-Response Relationship, Drug; Female; Fetal Death; Human | 2001 |
Platelet life span in pregnancies resulting in small-for-gestational age infants.
Topics: Aspirin; Blood Platelets; Cell Survival; Female; Fetal Growth Retardation; Humans; Infant, Newborn; | 1979 |
Assessment of whole-blood spontaneous platelet aggregation during pregnancy using an impedance particle counter.
Topics: Adolescent; Adult; Aspirin; Electric Impedance; Female; Fetal Growth Retardation; Gestational Age; H | 1992 |